Latest news
CRISPR Therapeutics posts 151% sales growth for CASGEVY, expands pipeline, and stays well-funded. - PluangPluang · Wed, 05 Aug 2026 19:53:17 GMTCRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310 (NASDAQ:CRSP) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 14:09:04 GMTWhy CRISPR Therapeutics (CRSP) Is Up 11.6% After CASGEVY Expansion And Pipeline Updates - And What's Next - simplywall.stsimplywall.st · Wed, 05 Aug 2026 04:44:10 GMTCiti Raises Price Target for CRISPR Therapeutics (CRSP) Amid Str - GuruFocusGuruFocus · Tue, 04 Aug 2026 18:22:30 GMTCrispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says - Yahoo FinanceYahoo Finance · Tue, 04 Aug 2026 15:49:54 GMTCRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - tradingview.comtradingview.com · Mon, 03 Aug 2026 22:19:13 GMTCRSP: CASGEVY revenue soared and net loss narrowed in Q2 2026, with major clinical and regulatory advances - tradingview.comtradingview.com · Mon, 03 Aug 2026 20:28:57 GMTSwitzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion - tradingview.comtradingview.com · Mon, 03 Aug 2026 20:26:45 GMT